Polyglutamate-medicament coupling compound with amino acid as communicating terminal

Polyglutamate-medicament coupling compound with amino acid as communicating terminal

The invention aims at providing a poly-glutamic acid-drug conjugate which takes amino acids as connectors and the non-toxic pharmaceutically acceptable salts, wherein, the drugs are gemcitabine, paclitaxel or docetaxel. The Alpha-carboxyl of the amino acid molecules are connected with 5'-hydrox...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: ZHANG ZHENQING, ZHANG JIANXIN, ZHONG BOHUA, SHI WEIGUO, XIE JIANWEI, CHEN LANFU
Format: Patent
Sprache:chi ; eng
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator ZHANG ZHENQING
ZHANG JIANXIN
ZHONG BOHUA
SHI WEIGUO
XIE JIANWEI
CHEN LANFU
description The invention aims at providing a poly-glutamic acid-drug conjugate which takes amino acids as connectors and the non-toxic pharmaceutically acceptable salts, wherein, the drugs are gemcitabine, paclitaxel or docetaxel. The Alpha-carboxyl of the amino acid molecules are connected with 5'-hydroxys of gemcitabine molucules or 2'-hydroxys of paclitaxel (docetaxel) molecules by ester bonds, and Alpha-aminos are connected with hydroxys of poly-(L)-glutamic acid molecules by amide bonds. The content of the gemcitabine in the conjugate is within the range of 5 to 30 percent (weight ratio), and the content of paclitaxel or docetaxel is within the range of 10 to 40 percent (weight ratio).
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CN101209350BB</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CN101209350BB</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CN101209350BB3</originalsourceid><addsrcrecordid>eNqNi7EKwjAURbM4iPoPwb2QWhxcWxQnceheHsmzBvJegnlB_HtT8AOc7oFz7lqN9xg-cygCBIINofMWCFm0jSUFz3MFSrGw028vTw3kOWqw3mnIi6PC9SJLKfiqFsJWrR4QMu5-u1H7y3kcrg2mOGFOYJFRpuHWmvZgTt3R9H33V_QFh_s6Hg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Polyglutamate-medicament coupling compound with amino acid as communicating terminal</title><source>esp@cenet</source><creator>ZHANG ZHENQING ; ZHANG JIANXIN ; ZHONG BOHUA ; SHI WEIGUO ; XIE JIANWEI ; CHEN LANFU</creator><creatorcontrib>ZHANG ZHENQING ; ZHANG JIANXIN ; ZHONG BOHUA ; SHI WEIGUO ; XIE JIANWEI ; CHEN LANFU</creatorcontrib><description>The invention aims at providing a poly-glutamic acid-drug conjugate which takes amino acids as connectors and the non-toxic pharmaceutically acceptable salts, wherein, the drugs are gemcitabine, paclitaxel or docetaxel. The Alpha-carboxyl of the amino acid molecules are connected with 5'-hydroxys of gemcitabine molucules or 2'-hydroxys of paclitaxel (docetaxel) molecules by ester bonds, and Alpha-aminos are connected with hydroxys of poly-(L)-glutamic acid molecules by amide bonds. The content of the gemcitabine in the conjugate is within the range of 5 to 30 percent (weight ratio), and the content of paclitaxel or docetaxel is within the range of 10 to 40 percent (weight ratio).</description><language>chi ; eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2011</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20110907&amp;DB=EPODOC&amp;CC=CN&amp;NR=101209350B$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76516</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20110907&amp;DB=EPODOC&amp;CC=CN&amp;NR=101209350B$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>ZHANG ZHENQING</creatorcontrib><creatorcontrib>ZHANG JIANXIN</creatorcontrib><creatorcontrib>ZHONG BOHUA</creatorcontrib><creatorcontrib>SHI WEIGUO</creatorcontrib><creatorcontrib>XIE JIANWEI</creatorcontrib><creatorcontrib>CHEN LANFU</creatorcontrib><title>Polyglutamate-medicament coupling compound with amino acid as communicating terminal</title><description>The invention aims at providing a poly-glutamic acid-drug conjugate which takes amino acids as connectors and the non-toxic pharmaceutically acceptable salts, wherein, the drugs are gemcitabine, paclitaxel or docetaxel. The Alpha-carboxyl of the amino acid molecules are connected with 5'-hydroxys of gemcitabine molucules or 2'-hydroxys of paclitaxel (docetaxel) molecules by ester bonds, and Alpha-aminos are connected with hydroxys of poly-(L)-glutamic acid molecules by amide bonds. The content of the gemcitabine in the conjugate is within the range of 5 to 30 percent (weight ratio), and the content of paclitaxel or docetaxel is within the range of 10 to 40 percent (weight ratio).</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2011</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNi7EKwjAURbM4iPoPwb2QWhxcWxQnceheHsmzBvJegnlB_HtT8AOc7oFz7lqN9xg-cygCBIINofMWCFm0jSUFz3MFSrGw028vTw3kOWqw3mnIi6PC9SJLKfiqFsJWrR4QMu5-u1H7y3kcrg2mOGFOYJFRpuHWmvZgTt3R9H33V_QFh_s6Hg</recordid><startdate>20110907</startdate><enddate>20110907</enddate><creator>ZHANG ZHENQING</creator><creator>ZHANG JIANXIN</creator><creator>ZHONG BOHUA</creator><creator>SHI WEIGUO</creator><creator>XIE JIANWEI</creator><creator>CHEN LANFU</creator><scope>EVB</scope></search><sort><creationdate>20110907</creationdate><title>Polyglutamate-medicament coupling compound with amino acid as communicating terminal</title><author>ZHANG ZHENQING ; ZHANG JIANXIN ; ZHONG BOHUA ; SHI WEIGUO ; XIE JIANWEI ; CHEN LANFU</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CN101209350BB3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>chi ; eng</language><creationdate>2011</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>ZHANG ZHENQING</creatorcontrib><creatorcontrib>ZHANG JIANXIN</creatorcontrib><creatorcontrib>ZHONG BOHUA</creatorcontrib><creatorcontrib>SHI WEIGUO</creatorcontrib><creatorcontrib>XIE JIANWEI</creatorcontrib><creatorcontrib>CHEN LANFU</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>ZHANG ZHENQING</au><au>ZHANG JIANXIN</au><au>ZHONG BOHUA</au><au>SHI WEIGUO</au><au>XIE JIANWEI</au><au>CHEN LANFU</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Polyglutamate-medicament coupling compound with amino acid as communicating terminal</title><date>2011-09-07</date><risdate>2011</risdate><abstract>The invention aims at providing a poly-glutamic acid-drug conjugate which takes amino acids as connectors and the non-toxic pharmaceutically acceptable salts, wherein, the drugs are gemcitabine, paclitaxel or docetaxel. The Alpha-carboxyl of the amino acid molecules are connected with 5'-hydroxys of gemcitabine molucules or 2'-hydroxys of paclitaxel (docetaxel) molecules by ester bonds, and Alpha-aminos are connected with hydroxys of poly-(L)-glutamic acid molecules by amide bonds. The content of the gemcitabine in the conjugate is within the range of 5 to 30 percent (weight ratio), and the content of paclitaxel or docetaxel is within the range of 10 to 40 percent (weight ratio).</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language chi ; eng
recordid cdi_epo_espacenet_CN101209350BB
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title Polyglutamate-medicament coupling compound with amino acid as communicating terminal
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T02%3A35%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=ZHANG%20ZHENQING&rft.date=2011-09-07&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECN101209350BB%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true